IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set a "buy" rating on the stock.

Several other brokerages have also commented on IDYA. Royal Bank Of Canada upgraded IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their target price for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. Wells Fargo & Company began coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target on the stock. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a research note on Thursday, July 10th. Finally, JPMorgan Chase & Co. upped their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a research note on Thursday, May 22nd. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, IDEAYA Biosciences has an average rating of "Moderate Buy" and a consensus target price of $47.55.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock traded down $0.12 on Tuesday, hitting $24.71. 277,886 shares of the company's stock traded hands, compared to its average volume of 1,150,516. IDEAYA Biosciences has a one year low of $13.45 and a one year high of $44.42. The company has a fifty day moving average of $21.35 and a two-hundred day moving average of $20.33. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -6.87 and a beta of 0.03.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the company posted ($0.53) earnings per share. Equities research analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Institutional Trading of IDEAYA Biosciences

Several institutional investors and hedge funds have recently modified their holdings of IDYA. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of IDEAYA Biosciences during the second quarter valued at approximately $216,000. KLP Kapitalforvaltning AS increased its position in shares of IDEAYA Biosciences by 16.1% during the second quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the company's stock valued at $364,000 after acquiring an additional 2,400 shares during the last quarter. Platinum Investment Management Ltd. increased its position in shares of IDEAYA Biosciences by 9.3% during the second quarter. Platinum Investment Management Ltd. now owns 166,917 shares of the company's stock valued at $3,509,000 after acquiring an additional 14,204 shares during the last quarter. Signaturefd LLC increased its position in shares of IDEAYA Biosciences by 58.1% during the second quarter. Signaturefd LLC now owns 4,549 shares of the company's stock valued at $96,000 after acquiring an additional 1,672 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in shares of IDEAYA Biosciences by 72.4% during the second quarter. Parallel Advisors LLC now owns 3,260 shares of the company's stock valued at $69,000 after acquiring an additional 1,369 shares during the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.